JG
AEGR

Jefferies Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

Jefferies Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-712,948
Closed -$2.12M – 2693
2016
Q3 		$2.12M Sell
712,948
-32,202
-4% -$55.8K 0.01% 910
2016
Q2 		$1.11M Buy
745,150
+447,027
+150% +$1.02M 0.01% 1114
2016
Q1 		$1.1M Buy
298,123
+75,623
+34% +$468K 0.01% 1098
2015
Q4 		$2.25M Buy
+222,500
New +$2.68M 0.01% 822
2015
Q3 		– Sell
-90
Closed -$2K – 3602
2015
Q2 		$2K Buy
+90
New +$1.95K ﹤0.01% 3175
2014
Q3 		– Sell
-95,435
Closed -$3.06M – 2642
2014
Q2 		$3.06M Buy
+95,435
New +$3.55M 0.03% 494
2013
Q4 		– Sell
-873
Closed -$75K – 2374
2013
Q3 		$75K Buy
+873
New +$74K ﹤0.01% 1736

Jefferies Group's AEGR Position: Q4 2016 in Review

Jefferies Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 712,948 shares — an estimated $2.12M sold.

Jefferies Group first reported a position in AEGR in Q3 2013 and held it in 7 quarters. The position peaked at $3.06M in Q2 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Jefferies Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Jefferies Group sold 712,948 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $2.12M.
  • Jefferies Group first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Jefferies Group's Aegerion Pharmaceuticals position peaked at $3.06M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Jefferies Group's 13F filing for Q4 2016, filed 14 Feb 2017.